CTRI/2023/09/057485尚未招募4 期
A Prospective Prescription Event Monitoring PEM surveillance of EMROK Levonadifloxacin injection and or EMROK O Levonadifloxacin tablet. - Emrok PEM 2023
Wockhardt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Adult (at least 18 years of age) patient of any gender prescribed with EMROK or/and EMROK-O and willing to provide written informed consent to share information
排除标准
- •1. Known to be hypersensitive to Levonadifloxacin and any other quinolone antibactrial or to any other excepients
研究者
相似试验
尚未招募
4 期
Real world study to evaluate the safety and efficacy of NUWOK tab and Injection in the patients have infection.CTRI/2024/04/065903Wockhardt Ltd
尚未招募
4 期
Prescription event monitoring study of Emrok injection and tabin the patient of diabetes foot ulcer.CTRI/2024/04/065615Wockhardt Ltd
尚未招募
不适用
Prescription Event Monitoring (PEM) for EMROK tablet and InjectionsCTRI/2021/08/035789Wockhardt Ltd
已完成
不适用
Real world data of patients across India will be retrospectively collected in this study of Levonadifloxacin.CTRI/2020/09/028152Wockhardt Limited
尚未招募
4 期
To Effects of ZincorespTM Syrup in Children Aged 2- 12 Years Having Respiratory Disorders and Infections.CTRI/2024/02/063048apex laboratories private limited